CpG, a well-known TLR9 agonist, enhances antitumor immunity by stimulating DCs to secrete pro-inflammatory cytokines, driving effective T cell responses, and facilitating the recognition of tumor-associated antigens (Sagiv-Barfi et al., 2016). The gene discussed is TLR9; the disease is neoplasm.